BrainStorm Cell Therapeutics Presents at the 11th International Conference on Alzheimer’s and Parkinson’s Disease

NEW YORK, NY and PETACH TIKVAH, ISRAEL--(Marketwire - Mar 8, 2013) - BrainStorm Cell Therapeutics ( OTCQB : BCLI ), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today a poster presentation of clinical and scientific data at the 11th International Conference on Alzheimer's and Parkinson's Diseases (AD/PD 2013) this week in Florence, Italy (http://www2.kenes.com/adpd/Pages/Home.aspx).

"We are excited to be presenting our NurOwn technology at this important meeting," said Alon Natanson, Chief Executive Officer of BrainStorm Cell Therapeutics. "The AD/PD Conference brings international medical professionals together for a dynamic scientific program revealing cutting-edge research and discoveries diagnosing, preventing, and treating neurodegenerative diseases.We believe that our groundbreaking data on NurOwn will be well received by the attendees."

In the coming months BrainStorm will be making a number of presentations at various international medical and research conferences as the scientific communities in Europe and the US are closely following the company's progress with its clinical development program.

About NurOwnNurOwn is an autologous, adult stem cell therapy technology that differentiates bone marrow-derived mesenchymal stem cells (MSC) into specialized, neuron-supporting cells.These neuron-supporting cells (known as "MSC-NTF" cells) secrete neurotrophic, or nerve-growth, factors for PROTECTION of existing motor neurons, PROMOTION of motor neuron growth, and RE-ESTABLISHMENT of nerve-muscle interaction.The ability to differentiate mesenchymal stem cells into MSC-NTF cells, and confirmation of their activity and potency before transplantation, makes NurOwn a first-of-its-kind approach for treating neurodegenerative diseases.More information about NurOwn can be found at http://brainstorm-cell.com/index.php/science-a-technology/-nurown.

About BrainStorm Cell Therapeutics, Inc.BrainStorm Cell Therapeutics, Inc. is a biotechnology company engaged in the development of first-of-its-kind adult stem cell therapies derived from autologous bone marrow cells for the treatment of neurodegenerative diseases. The Company holds the rights to develop and commercialize its NurOwn technology through an exclusive, worldwide licensing agreement with Ramot, the technology transfer company of Tel Aviv University. For more information, visit the company's website at http://www.brainstorm-cell.com.

Safe Harbor Statement - Statements in this announcement other than historical data and information constitute "forward-looking statements" and involve risks and uncertainties that could cause BrainStorm Cell Therapeutics Inc.'s actual results to differ materially from those stated or implied by such forward-looking statements. Terms and phrases such as "may", "should", "would", "could", "will", "expect", "likely", "believe", "plan", "estimate", "predict", "potential", and similar terms and phrases are intended to identify these forward-looking statements.The potential risks and uncertainties include, without limitation, risks associated with BrainStorm's limited operating history, history of losses; minimal working capital, dependence on its license to Ramot's technology; ability to adequately protect the technology; dependence on key executives and on its scientific consultants; ability to obtain required regulatory approvals; and other factors detailed in BrainStorm's annual report on Form 10-K and quarterly reports on Form 10-Q available at http://www.sec.gov.These factors should be considered carefully, and readers should not place undue reliance on BrainStorm's forward-looking statements.The forward-looking statements contained in this press release are based on the beliefs, expectations and opinions of management as of the date of this press release. We do not assume any obligation to update forward-looking statements to reflect actual results or assumptions if circumstances or management's beliefs, expectations or opinions should change, unless otherwise required by law. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.

See the original post:
BrainStorm Cell Therapeutics Presents at the 11th International Conference on Alzheimer's and Parkinson's Disease

Type 1 diabetes wreaks havoc, cure would be welcome

Re "Can stem cell treatment cure Type 1 diabetes?" (Forum, March 3): As someone who has survived for 47 years with Type 1 diabete,s I've seen just about everything go wrong that possibly could including retinopathy, neuropathy and acute hypoglycemic unawareness. I read with great interest the article regarding a potential cure through the device being set for testing by ViaCyte using cloned beta cells to produce insulin normally.

I survived as a child in the early 1960s through the efforts of a mother who sacrificed greatly to provide me with an as normal as possible childhood. It wasn't until the birth of my daughter that I realized just how great her level of anxiety must have truly been.

Type 1 diabetes is an insidious disease that can wreak havoc on even those who do everything right in caring for themselves. It demands full time vigilance of those who live with it and a cure is a dream of mine.

-- James D.Taylor, Elk Grove

Copyright The Sacramento Bee. All rights reserved.

What You Should Know About Comments on Sacbee.com

Sacbee.com is happy to provide a forum for reader interaction, discussion, feedback and reaction to our stories. However, we reserve the right to delete inappropriate comments or ban users who can't play nice. (See our full terms of service here.)

Here are some rules of the road:

Keep your comments civil. Don't insult one another or the subjects of our articles. If you think a comment violates our guidelines click the "Report Abuse" link to notify the moderators. Responding to the comment will only encourage bad behavior.

Don't use profanities, vulgarities or hate speech. This is a general interest news site. Sometimes, there are children present. Don't say anything in a way you wouldn't want your own child to hear.

View original post here:
Type 1 diabetes wreaks havoc, cure would be welcome

Adult Stem Cell Treatment for Toddler with Cerebral Palsy – Video

Adult Stem Cell Treatment for Toddler with Cerebral Palsy
A WCBS news report by health correspondent, Dr. Max Gomez. Dr. Gomez tells the story of little Chloe, who suffers from cerebral palsy and could barely crawl as a symptom of a stroke. Adult stem cells banked at her birth from her cord blood were turned into a treatment for this debilitating disease. Chloe showed remarkable improvement, now being able to stand, run and dance around the house.

By: StemForLife

Here is the original post:
Adult Stem Cell Treatment for Toddler with Cerebral Palsy - Video

Osiris Therapeutics Reports Fourth Quarter and Full Year 2012 Financial Results

COLUMBIA, Md.--(BUSINESS WIRE)--

Osiris Therapeutics, Inc. (OSIR) the leading stem cell company focused on developing and marketing products to treat medical conditions in inflammatory, cardiovascular, orthopedic and wound healing markets, announced today its results for the fourth quarter and full year ended December 31, 2012.

Recent and Full Year Highlights

With the approval of Prochymal, 2012 was an historic year for the entire field of stem cell medicine, said C. Randal Mills, Ph.D., President and Chief Executive Officer of Osiris. For Osiris, it was also a year of commercial transformation, having four products on the market and expanding capabilities in development, manufacturing, sales and marketing. Osiris is now a fully integrated commercial cell therapy company, well-positioned for future growth.

Fourth Quarter Financial Results

Revenues during the fourth quarter of 2012 were $3.1 million, including Biosurgery product revenues of $2.9 million compared to $0.8 million over the same period of 2011. Gross margin during the fourth quarter was 70% compared to 58% during the fourth quarter of 2011. Gross profit was $2.1 million during the fourth quarter of 2012 and $0.4 million during the same period of 2011. We reported a loss of $2.6 million in the fourth quarter of 2012. As of December 31, 2012, Osiris had $37.2 million in cash, receivables and short-term investments.

Research and development expenses for the fourth quarter of 2012 were $3.1 million, compared to $4.2 million incurred in the fourth quarter of 2011. General and administrative expenses were $1.8 million for the fourth quarter of 2012, compared to $1.5 million for the same period of the prior year.

Full Year 2012 Financial Highlights

Revenues of $11.8 million were recognized in 2012, including $7.8 million in Biosurgery product revenues compared to $1.3 million over the same period in 2011. We recognized $42.4 million of total revenues in 2011, including $40.0 million from the Genzyme collaboration agreement, $1.0 million from the research, development and commercialization agreement with the JDRF and $1.3 million of revenues from our Biosurgery products. Gross margin during 2012 was 67% compared to 58% during 2011. Gross profit was $5.3 million during fiscal 2012 and $0.7 million during fiscal 2011. We reported a loss of $11.1 million for the fiscal year ended December 31, 2012.

R&D expenses for the 2012 fiscal year were $14.1 million compared to $19.2 million in the prior year. G&A expenses in fiscal 2012 were $6.3 million, whereas G&A expenses in 2011 were $7.9 million, including $2.6 million of non-cash share-based payments.

See more here:
Osiris Therapeutics Reports Fourth Quarter and Full Year 2012 Financial Results

Stem cell research focusing on autism’s genetic mysteries earns $2.125 million grant

The social symbol for autism awareness, a ribbon of brightly colored puzzle pieces, reflects the complexity of autism spectrum disorder (ASD).A new five-year $2.125 million grant from the New Jersey Governors Council for Medical Research and Treatment of Autism will fund research of induced pluripotent stem cells that may be used to piece together the genetic pathways of autism and lead to new treatments for individuals affected by ASD.The research, led by James H. Millonig Ph.D., associate professor of neuroscience and cell biology at the University of Medicine and Dentistry of New Jersey Robert Wood Johnson Medical School, is being conducted as part of the Robert Wood Johnson Medical School New Jersey Autism Center of Excellence (NJ ACE).

Autism is defined by a spectrum of behavioral and neurological abnormalities, with distinct characteristics for each individual denoting that there are multiple underlying genetic causes, said Dr. Millonig, who also is assistant dean of medical science training at Robert Wood Johnson Medical School and a member of the Center for Advanced Biotechnology and Medicine, a joint institute of the medical school and Rutgers,The State University of New Jersey. Working with my colleagues in neuroscience and at the Child Health Institute of New Jersey and Rutgers, we hope to identify the neurobiological, molecular and genetic basis the biological signature of autism.

Autism is a disorder of the brain, which is mostly comprised of neurons. Induced pluripotent stem cells (iPSCs) are scientifically derived stem cells from individuals that mimic the traits of embryonic stem cells and can be used to create other cell types.Therefore, the research team will use iPSCs to create human neurons in order to understand how they develop abnormally in individuals with autism.The scientists will then test FDA-approved drugs on the neurons to identify therapeutic treatments that may improve or reverse the disorder.

We know of a lot of genes associated with autism, but dont know when, where and how they act in development, explains Dr. Millonig.We need to look at neurons and determine how they mature differently in order to develop better drug therapies that are tailored to the needs of individuals with autism.

The multi-institutional N.J.ACE team includes Emanuel DiCicco- Bloom M.D., professor of neuroscience and cell biology and pediatrics at the medical school; Linda M. Brzustowicz M.D., professor of genetics, Rutgers University; Chi-wei Lu Ph.D., assistant professor of obstetrics, gynecology, and reproductive sciences; and Zhiping Pang Ph.D., assistant professor of neuroscience and cell biology both at the Child Health Institute of New Jersey; and Yong Lin Ph.D., at The Cancer Institute of New Jersey.The Child Health Institute of New Jersey and The Cancer Institute of New Jersey are Centers of Excellence at Robert Wood Johnson Medical School. Consultants on the grant include the Rutgers University Cell and DNA Repository; Ronald Hart Ph.D., professor of cell biology and neuroscience, Rutgers University; Bonnie Firestein Ph.D., professor of cell biology and neuroscience, Rutgers University; Jennifer Moore Ph.D., associate director, National Institute of Mental Health Stem Cell Center, and research assistant director, Stem Cell Research Center, Rutgers University.

To learn more about UMDNJRobert Wood Johnson Medical School, log on to rwjms.umdnj.edu.

Original post:
Stem cell research focusing on autism’s genetic mysteries earns $2.125 million grant

Generosity of parents who gave away £22,000 raised for their seriously ill daughter to help little boy they’ve never …

Abigail Williams, 7, suffers from Batten Disease, a fatal genetic disorder Her parents hoped money would pay for successful stem cell treatment But doctors say any procedure would be futile as condition is incurable So they have donated cash to Kyle Weaver, 3, for spinal operation in U.S.

By Simon Tomlinson

PUBLISHED: 06:37 EST, 6 March 2013 | UPDATED: 13:30 EST, 6 March 2013

A kindhearted couple have given away 22,500 raised for their seriously ill daughter to help a sick child they've never met after being told the money would not find a cure for their little girl.

Kevin and Christine Williams hoped the cash would pay for successful stem cell treatment for seven-year-old Abigail, who suffers from a fatal genetic disease.

But they have been told her condition is incurable and paying thousands for any further procedures would be futile.

Overwhelming generosity: Christine Wililams (left) and her husband Kevin have given away 22,500 to help a boy to walk for the first time after being told the money wouldn't cure their daughter Abigail (right)

For a new lease of life: The Williams family have donated the money to three-year-old Kyle Weaver (pictured) who they have never met so he can have an operation to help him walk

So they have decided to donate the money meant to help toddler Kyle Weaver, three, walk for the first time.

Kevin said: 'It's not fair for us to have 22,500 sitting in a bank while hoping for a cure that may never come, while another little boy is sick and needs the money for an operation.

View original post here:
Generosity of parents who gave away £22,000 raised for their seriously ill daughter to help little boy they've never ...

YaFarm Technologies Announces Funding for ISCI

PITTSTON, ME--(Marketwire - Mar 6, 2013) - YaFarm Technologies, Inc. ( PINKSHEETS : YFRM ) (YaFarm, or the Company) announced today that the Integrative Stem Cell Institute (ISCI) has received significant funding for its venture in Cancun, Mexico.

The ISCI is a premier provider of cell-based, regenerative medical therapies that utilize a patient's own stem cells for the treatment of neuro-degenerative diseases. Combining a state-of-the-art laboratory and clean room facility with an integrative medical approach to treatment, the ISCI provides therapies as part of controlled clinical studies. The ISCI has partnered with the International Stem Cell Practice (ISCP) to provide patients with access to a global network of physicians to provide pre-treatment evaluation and post-therapy follow up for the independent collection and evaluation of patient outcomes.

The investment will be used to complete the construction of the new medical facility housed within Hospital Galenia in Cancun, Mexico. The hospital is accredited by both the Joint Commission (JCI) and the Accreditation Canada (ACI), and is the only hospital in Mexico to have been awarded certification from both of these organizations.

"The funding is important," says David Audley, CEO of the ISCI. "The pace of work for both the laboratory facility and the clean room space is moving fast, and this final infusion of capital will allow us to complete the project earlier than scheduled." Once finished, the ISCI will be able to initiate the clinical studies for diseases such as Parkinson's, Alzheimer's and Multiple Sclerosis.

"This last stage financing allows us to deliver these therapies to patients sooner than we expected," continues Mr Audley. "With a state-of-the-art lab, a world-class medical facility and a truly integrative treatment approach represent the next great stage of cell-based medicine, and patient care."

About Integrative Stem Cell Institute (ISCI)

The Integrative Stem Cell Institute (ISCI) is a premier provider of point-of-care, stem cell-based therapies for patients from around the world. With a state of the art laboratory housed within the Hospital Galenia in Cancun, Mexico, the ISCI combines the most advanced scientific application of stem cells with second to none medical care within the structure of adaptive clinical trials to effectively track long term outcomes and assure patient safety. More information on the Integrative Stem Cell Institute is available at http://www.iscelli.com

SAFE HARBOR STATEMENT

This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward looking statements are subject include, but are not limited to, the effect of government regulation, competition, adequate financing, and other material risks. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance, or achievements to be materially different from the statements made herein.

Original post:
YaFarm Technologies Announces Funding for ISCI

International Stem Cell Corporation to Present at 65th American Academy of Neurology Annual Meeting

CARLSBAD, CA--(Marketwire - Mar 5, 2013) - International Stem Cell Corporation ( OTCQB : ISCO ) (www.internationalstemcell.com) a California-based biotechnology company focused on the therapeutic applications of human parthenogenetic stem cells announced today that it will present results of pre-clinical studies of Parkinson's disease (PD) at the 65th American Academy of Neurology Annual Meeting at the San Diego Convention Center, San Diego, California on Wednesday, March 20th, 2013.

At the meeting Dr. Ruslan Semechkin, Vice President of Research and Development for ISCO, will present results from efficacy studies of stem cell derived neuronal cells for the treatment of Parkinson's disease. Results and conclusions from both rodent and non-human primate models of the disease will be presented.

The American Academy of Neurology Annual Meeting is one of the world's most important annual events for neurologists and neuroscience professionals and the largest such international meeting of its kind with more than 12,000 attendees at last year's meeting.

About International Stem Cell Corporation

International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs) hence avoiding ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenetic, homozygous stem cell line that can be a source of therapeutic cells for hundreds of millions of individuals of differing genders, ages and racial background with minimal immune rejection after transplantation. hpSCs offer the potential to create the first true stem cell bank, UniStemCell. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology (www.lifelinecelltech.com), and stem cell-based skin care products through its subsidiary Lifeline Skin Care (www.lifelineskincare.com). More information is available at http://www.internationalstemcell.com.

To receive ongoing corporate communications via email, visit: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0

To like our Facebook page or follow us on Twitter for company updates and industry related news, visit: http://www.facebook.com/InternationalStemCellCorporation and http://www.twitter.com/intlstemcell

More here:
International Stem Cell Corporation to Present at 65th American Academy of Neurology Annual Meeting

Part 16, after stem cell treatment, 3 months already! 2march2013 – Video

Part 16, after stem cell treatment, 3 months already! 2march2013
Please note I made an error saying the date, it was the 2 March 2013 My name is Carole St-Laurent, I am from Rimouski, Quebec, Canada. I have a Spinal Muscular Atrophy from birth, it #39;s in the family of Muscular Dystrophy. I received a stem cell treatment on the 28th of November 2012 at the "Integra Medical Center" in Nuevo Progresso Mexico, by Dr. Omar Gonzalez. This is a follow-up video.

By: Kina Diamond

Continue reading here:
Part 16, after stem cell treatment, 3 months already! 2march2013 - Video